Compare Enveric Biosciences Inc (ENVB) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kimberly Clark Corp — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Kimberly Clark Corp trades at $108.69 (market cap $35.36B). The key difference: Kimberly Clark Corp is far larger — about 6646.6× Enveric Biosciences Inc's market cap, and Kimberly Clark Corp pays a 4.81% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KMB | |
|---|---|---|
Market Cap | $5.32M | $35.36B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $136.77 |
52-Week Low | $1.28 | $93.05 |
Enterprise Value | $408.82K | $41.90B |
Dividend Yield | — | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Kimberly-Clark (KMB) trades at $108.92, up 1.97% with a bullish technical signal despite mixed moving averages. The company maintains strong profitability with a 12.8% net income margin and has beaten earnings estimates for three consecutive quarters. Recent developments include the Arbex joint venture and pending Kenvue acquisition, positioning for strategic transformation while maintaining its Dividend King status with consistent payouts.
KMB offers stable income appeal with a 4.5% dividend yield and analyst consensus target of $112.33, suggesting modest upside. Risks include consumer sentiment pressures and margin compression from input costs, but productivity gains and innovation strategy support long-term growth potential for patient investors seeking reliable cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
